Preliminary Findings Associate Hippocampal
Journal
AJNR. American journal of neuroradiology
ISSN: 1936-959X
Titre abrégé: AJNR Am J Neuroradiol
Pays: United States
ID NLM: 8003708
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
01
04
2020
accepted:
17
08
2020
pubmed:
14
11
2020
medline:
23
3
2021
entrez:
13
11
2020
Statut:
ppublish
Résumé
Previous hippocampal proton MR spectroscopic imaging distinguished patients with schizophrenia from controls by elevated Cr levels and significantly more variable NAA and Cho concentrations. This goal of this study was to ascertain whether this metabolic variability is associated with clinical features of the syndrome, possibly reflecting heterogeneous hippocampal pathologies and perhaps variability in its "positive" (psychotic) and "negative" (social and emotional deficits) symptoms. In a sample of 15 patients with schizophrenia according to the The patient cohort comprised 8 men and 7 women (mean age, 39.1 [SD, 10.8] years, with a mean disease duration of 17.2 [SD, 10.8] years. Despite the relatively modest cohort size, we found the following: 1) Elevated Cho levels predict the positive (psychotic, These preliminary findings suggest that NAA and Cho variations reflect different pathophysiologic processes, consistent with microgliosis/astrogliosis and/or lower vitality (reduced NAA) and demyelination (elevated Cho). In particular, the active state-related symptoms, including psychosis and mania, were associated with demyelination. Consequently, their deviations from the means of healthy controls may be a marker that may benefit precision medicine in selection and monitoring of schizophrenia treatment.
Sections du résumé
BACKGROUND AND PURPOSE
Previous hippocampal proton MR spectroscopic imaging distinguished patients with schizophrenia from controls by elevated Cr levels and significantly more variable NAA and Cho concentrations. This goal of this study was to ascertain whether this metabolic variability is associated with clinical features of the syndrome, possibly reflecting heterogeneous hippocampal pathologies and perhaps variability in its "positive" (psychotic) and "negative" (social and emotional deficits) symptoms.
MATERIALS AND METHODS
In a sample of 15 patients with schizophrenia according to the
RESULTS
The patient cohort comprised 8 men and 7 women (mean age, 39.1 [SD, 10.8] years, with a mean disease duration of 17.2 [SD, 10.8] years. Despite the relatively modest cohort size, we found the following: 1) Elevated Cho levels predict the positive (psychotic,
CONCLUSIONS
These preliminary findings suggest that NAA and Cho variations reflect different pathophysiologic processes, consistent with microgliosis/astrogliosis and/or lower vitality (reduced NAA) and demyelination (elevated Cho). In particular, the active state-related symptoms, including psychosis and mania, were associated with demyelination. Consequently, their deviations from the means of healthy controls may be a marker that may benefit precision medicine in selection and monitoring of schizophrenia treatment.
Identifiants
pubmed: 33184071
pii: ajnr.A6879
doi: 10.3174/ajnr.A6879
pmc: PMC7814798
doi:
Substances chimiques
Aspartic Acid
30KYC7MIAI
Choline
N91BDP6H0X
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
88-93Subventions
Organisme : NIA NIH HHS
ID : P30 AG066512
Pays : United States
Organisme : NIBIB NIH HHS
ID : U24 EB028980
Pays : United States
Informations de copyright
© 2021 by American Journal of Neuroradiology.
Références
Chem Rev. 2010 May 12;110(5):3060-86
pubmed: 20387805
Magn Reson Med. 1998 Dec;40(6):822-31
pubmed: 9840826
NMR Biomed. 2012 Dec;25(12):1392-400
pubmed: 22714729
Nat Rev Neurosci. 2011 Sep 07;12(10):585-601
pubmed: 21897434
Tidsskr Nor Laegeforen. 2013 Apr 23;133(8):850-3
pubmed: 23612107
Cereb Cortex. 2017 Oct 1;27(10):5001-5013
pubmed: 28922832
Br J Soc Clin Psychol. 1967 Dec;6(4):278-96
pubmed: 6080235
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Alzheimers Dement. 2015 Feb;11(2):126-38
pubmed: 25130658
Neuropsychobiology. 2012;66(1):44-9
pubmed: 22797276
Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4746-51
pubmed: 11296301
AJNR Am J Neuroradiol. 2016 Dec;37(12):2273-2279
pubmed: 27444940
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Aug 30;86:340-352
pubmed: 29580804
Psychiatry Res. 2015 Jun 30;232(3):219-25
pubmed: 25896442
Eur Arch Psychiatry Clin Neurosci. 2009 Jun;259(4):203-11
pubmed: 19224116
J Neurosci Res. 2005 May 15;80(4):562-75
pubmed: 15825192
Trends Neurosci. 2008 May;31(5):234-42
pubmed: 18395805
Front Psychiatry. 2019 May 13;10:298
pubmed: 31133894
J Magn Reson Imaging. 2011 Dec;34(6):1251-61
pubmed: 22102558
Alzheimers Dement. 2015 Feb;11(2):111-25
pubmed: 25267715
Neurosci Biobehav Rev. 2009 Mar;33(3):232-52
pubmed: 18786562
Biol Psychiatry Cogn Neurosci Neuroimaging. 2017 Jan;2(1):20-27
pubmed: 29560884
Br J Psychiatry. 1978 Nov;133:429-35
pubmed: 728692
Magn Reson Med. 2006 Jul;56(1):34-40
pubmed: 16767711
Brain Imaging Behav. 2012 Mar;6(1):49-60
pubmed: 22045236
Methods Mol Biol. 2011;711:203-26
pubmed: 21279603
World Psychiatry. 2017 Oct;16(3):251-265
pubmed: 28941089
Curr Top Behav Neurosci. 2010;4:529-53
pubmed: 21312412
Dialogues Clin Neurosci. 2013 Sep;15(3):329-37
pubmed: 24174904
Am J Psychiatry. 2004 Jun;161(6):1116-8
pubmed: 15169703
Neuron. 2013 Apr 10;78(1):81-93
pubmed: 23583108
Transl Psychiatry. 2016 Aug 09;6(8):e868
pubmed: 27505231
Schizophr Bull. 2020 Feb 26;46(2):432-441
pubmed: 31424555